BridgeBio Pharma CAO Maricel Apuli Sells 2,000 Shares Under Rule 10b5-1 Plan
BridgeBio Pharma, Inc.
Subscribe to track BBIO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BridgeBio Pharma, Inc. ($BBIO) Form 4 Alert Insider: Maricel Apuli (Chief Accounting Officer) Transaction: Sale of 2,000 Common Stock shares @ $72.85 ($145,700 total value) Post-Transaction Holdings: 120,687 shares Significance: Low (Pre-arranged Rule 10b5-1 plan adopted Sep 8, 2025)
Comprehensive Analysis
Executive Summary
On October 30, 2026, Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. ($BBIO), sold 2,000 shares of common stock at a price of $72.85 per share for a total transaction value of $145,700. Following this transaction, Apuli directly holds 120,687 shares.
Transaction Analysis
- 10b5-1 Trading Plan: The disposition was executed pursuant to a pre-established Rule 10b5-1 sales plan adopted on September 8, 2025.
- Holding Impact: The sale represents approximately 1.63% of the insider's prior holdings (122,687 shares), leaving them with substantial equity exposure (120,687 shares remaining).
- Market Signal: Because the sale was conducted under a planned Rule 10b5-1 mechanism and involves a modest percentage of total holdings, the trading significance is considered Low.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.